NCT07074496View on ClinicalTrials.gov

Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2028

Conditions
Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Interventions
DRUG

ThisCART19A

ThisCART19A is a new type CAR-T therapy for patients with ph+ ALL.

DRUG

Fludarabine

Fludarabine is used for lymphodepletion.

DRUG

Cyclophosphamide

Cyclophosphamide is used for lymphodepletion.

DRUG

Olverembatinib

a third-generation TKI

Trial Locations (2)

215000

The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou

215006

The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou

Sponsors
All Listed Sponsors
collaborator

Fundamenta Therapeutics, Ltd.

INDUSTRY

lead

The First Affiliated Hospital of Soochow University

OTHER